Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi ATU Announces Licensing Agreement with Janssen for TESSA\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Interius BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by WuXi Advanced Therapies

    Menu

    WuXi Advanced Therapies

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              WuXi Advanced Therapies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

              Details:

              Under the agreement, WuXi ATU will serve as a cell processing manufacturing partner for the planned global clinical development of CABA-201, a 4-1BB-containing fully human CD19-CAR T, in systemic lupus erythematosus and idiopathic inflammatory myopathies, or myositis.

              Lead Product(s): CABA-201

              Therapeutic Area: Immunology Product Name: CABA-201

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Cabaletta Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              WuXi Advanced Therapies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies

              Details:

              Through the partnership, Interius will leverage WuXi ATU's CTDMO platform for Good Manufacturing Process (GMP) manufacturing of Phase I clinical product and will advance INT-2104 in vivo CART program for B cell malignancies to the clinic.

              Lead Product(s): INT-2104

              Therapeutic Area: Oncology Product Name: INT-2104

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Interius BioTherapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              WuXi Advanced Therapies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

              Details:

              Under this agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems.

              Lead Product(s): Aav Vectors

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY